Host-Microbe Interactions in Biliary Dilatation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-15

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an observational cohort study aimed at continuously enrolling patients with biliary dilatation and healthy controls. It will collect bile duct tissue samples and clinical data from participants across all age groups to establish a comprehensive cohort for biliary dilatation research. Based on this cohort, the study seeks to investigate the molecular mechanisms underlying biliary dilatation development and progression, explore the role of host-microbiome interactions in disease processes, and identify biomarkers associated with complications and malignancy risk, to establish evidence-based strategies for improved diagnosis and treatment of biliary dilatation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biliary Dilatation National Special Disease Cohort in China

NCT06881004

Choledochal Cyst

RECRUITING

Clinical Features and Prognosis of Asymptomatic Biliary Dilatation

NCT07028164

Choledochal Cyst

COMPLETED

Explore the Effects and Mechanisms of ERCP and EST on Biliary Microecology

NCT05592795

Cholangiopancreatography, Endoscopic Retrograde Choledocholithiasis Gallstones

UNKNOWN

Efficacy and Safety of Surgical Treatment for Type IVa CBD

NCT07036848

Choledochal Cyst

RECRUITING

Study of Microbiota in Bile From Patients With Common Bile Duct Stone During ERCP

NCT03490383

Cholangiopancreatography, Endoscopic Retrograde Common Bile Duct Calculi Microbial Colonization

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Biliary dilatation (BD) is a complex bile duct disease that affects people differently around the world. In Asia, about 1 in every 1,000 people have this condition. In Europe and America, it is much less common, affecting about 1 in every 50,000 to 150,000 people.

People with biliary dilatation face serious health risks. Up to 80% of patients develop complications such as bile duct inflammation (cholangitis) and bile duct stones. Even more concerning, about 30% of patients may develop cancer, and this risk increases with age. Even after surgery to remove the affected bile ducts, patients still face ongoing risks. About 35% continue to have problems with gallstones and bile duct inflammation. Their risk of developing cancer remains 120 to 200 times higher than healthy people, with cancer rates reaching 14.9%.

Despite these serious risks, researchers do not fully understand why biliary dilatation happens, how it gets worse over time, or why it leads to so many complications and such high cancer risk. Very few studies have looked at this disease at the molecular level. One study that examined genes did not find typical genetic changes. Other small studies looking at gene activity and proteins were limited by having too few patients and no comparison groups, so they could not find clear biological patterns.

Recent research has shown that bacteria and other microorganisms play important roles in many bile duct diseases, including bile duct stones, inflammation, and cancer. Because these microorganisms affect so many bile duct conditions, we believe they may also be important in biliary dilatation.

This study aims to create two groups of participants: people with biliary dilatation of all ages and a control group of healthy people. We will collect bile duct tissue samples from patients who have surgery to remove diseased bile ducts and from healthy donor bile duct tissue that would otherwise be discarded during organ transplant surgeries.

Through studying these tissue samples, our research team will work to understand how biliary dilatation develops and gets worse, why complications happen, and what role bacteria and other microorganisms play in this disease process.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Choledochal Cyst

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

This group included BD patients

No interventions assigned to this group

This group included healthy control

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who have been definitively diagnosed with biliary dilatation and are scheduled for surgical resection (Disease group) Healthy donor bile duct tissues discarded during organ transplantation procedures as part of routine surgical preparation (Control group)

Exclusion Criteria

Patients with severe systemic diseases that may affect study outcomes (Disease group) Insufficient tissue sample quality or quantity (Disease group) Unavailable or inadequate donor bile duct tissue samples (Control group)

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes